Related Experiment Video
Updated: Nov 30, 2025

A Screenable In Vivo Assay for Mitochondrial Modulators Using Transgenic Bioluminescent Caenorhabditis elegans
Published on: October 16, 2015
Multiple metabolic changes mediate the response of Caenorhabditis elegans to the complex I inhibitor rotenone
Claudia P Gonzalez-Hunt1, Anthony L Luz1, Ian T Ryde1
1Department of Nicholas School of the Environment, Duke University, Durham, NC, 27708, United States.
Abstract:
Rotenone, a mitochondrial complex I inhibitor, has been widely used to study the effects of mitochondrial dysfunction on dopaminergic neurons in the context of Parkinson's disease. Although the deleterious effects of rotenone are well documented, we found that young adult Caenorhabditis elegans showed resistance to 24 and 48 h rotenone exposures. To better understand the response to rotenone in C. elegans, we evaluated mitochondrial bioenergetic parameters after 24 and 48 h exposures to 1 μM or 5 μM rotenone. Results suggested upregulation of mitochondrial complexes II and V following rotenone exposure, without major changes in oxygen consumption or steady-state ATP levels after rotenone treatment at the tested concentrations. We found evidence that the glyoxylate pathway (an alternate pathway not present in higher metazoans) was induced by rotenone exposure; gene expression measurements showed increases in mRNA levels for two complex II subunits and for isocitrate lyase, the key glyoxylate pathway enzyme. Targeted metabolomics analyses showed alterations in the levels of organic acids, amino acids, and acylcarnitines, consistent with the metabolic restructuring of cellular bioenergetic pathways including activation of complex II, the glyoxylate pathway, glycolysis, and fatty acid oxidation. This expanded understanding of how C. elegans responds metabolically to complex I inhibition via multiple bioenergetic adaptations, including the glyoxylate pathway, will be useful in interrogating the effects of mitochondrial and bioenergetic stressors and toxicants.
Insights
Young C. elegans resist rotenone, a Parkinson's disease model toxin. Instead of damage, they activate alternative metabolic pathways like the glyoxylate pathway to cope with mitochondrial complex I inhibition.
Area of Science:
- Cellular biology
- Neuroscience
- Biochemistry
Background:
- Rotenone is a mitochondrial complex I inhibitor used to model Parkinson's disease.
- Dopaminergic neurons are typically vulnerable to rotenone-induced mitochondrial dysfunction.
- Young adult Caenorhabditis elegans exhibit unexpected resistance to rotenone exposure.
Purpose of the Study:
- To investigate the metabolic response of C. elegans to rotenone.
- To understand the mechanisms underlying rotenone resistance in C. elegans.
- To explore adaptations in mitochondrial bioenergetics and metabolic pathways.
Main Methods:
- Exposure of C. elegans to rotenone (1 μM or 5 μM) for 24 and 48 hours.
- Evaluation of mitochondrial bioenergetic parameters.
- Gene expression analysis for mitochondrial and glyoxylate pathway enzymes.
- Targeted metabolomics to analyze metabolic profiles.
Main Results:
- Upregulation of mitochondrial complexes II and V observed.
- No significant changes in oxygen consumption or ATP levels.
- Induction of the glyoxylate pathway, evidenced by increased isocitrate lyase mRNA.
- Metabolic restructuring including activation of complex II, glyoxylate pathway, glycolysis, and fatty acid oxidation.
Conclusions:
- C. elegans employs multiple bioenergetic adaptations to counteract rotenone-induced mitochondrial complex I inhibition.
- The glyoxylate pathway plays a role in the metabolic response to rotenone.
- This study provides insights into cellular resilience against mitochondrial toxins.
Related Concept Videos
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
The Electron Transport Chain
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q...

